Daniele Santini

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

Retrospective Consortium Analysis, Medicine, Pathology +5

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

Fotios Loupakis, Annamaria Ruzzo, Chiara Cremolini et al. · British Journal of Cancer · 2009 · 557 citations · Full text

Bone health in cancer: ESMO Clinical Practice Guidelines

Robert E. Coleman, Peyman Hadji, Jean‐Jacques Body et al. · Annals of Oncology · 2020 · 481 citations · Full text

The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline

Massimo Di Maïo, Ethan Basch, Fabrice Denis et al. · Annals of Oncology · 2022 · 435 citations · Full text

Surgical Oncology, Medicine, Cancer Management +10

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

Fotios Loupakis, Luca Emanuele Pollina, I. Stasi et al. · Journal of Clinical Oncology · 2009 · 402 citations · Full text